Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Lansoprazole is a proton pump inhibitor (PPI) with actions and uses similar to those of omeprazole. It is indicated in the treatment of peptic ulcer and gastroesophageal reflux. Oral administration once daily.
At latest update, relevant information on excretion into breast milk was not found.
Its pharmacokinetic data (very high percentage of protein binding, very wide volume of distribution and short half-life) make it highly unlikely that significant quantities will pass into breast milk.
Both Omeprazole and Pantoprazole, from the same pharmacological group (PPI) and with similar pharmacokinetic characteristics, are excreted in insignificant amounts in breast milk.
Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food.
It is a medication used in neonates and young infants. (AEP 2020)
Hyperprolactinemia and galactorrhea have been reported by the use of such medication (Duwicquet 2017, Jabbar 2010, Izquierdo 2004), though some authors have failed to show the same findings. (Dammann 1994 &1993)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.